Cargando…
Performance of the LumiraDx Microfluidic Immunofluorescence Point-of-Care SARS-CoV-2 Antigen Test in Asymptomatic Adults and Children
OBJECTIVES: The LumiraDx SARS-CoV-2 Ag Test has previously been shown to accurately detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals symptomatic for coronavirus disease 2019 (COVID-19). This evaluation investigated the LumiraDx SARS-CoV-2 Ag Test as an aid in the di...
Autores principales: | Drain, Paul, Sulaiman, Raed, Hoppers, Melanie, Lindner, Nigel M, Lawson, Vicki, Ellis, Jayne E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973256/ https://www.ncbi.nlm.nih.gov/pubmed/34668536 http://dx.doi.org/10.1093/ajcp/aqab173 |
Ejemplares similares
-
Performance Evaluation of the Quantitative Point-of-Care LumiraDx d-Dimer Test
por: Ellis, Jayne E., et al.
Publicado: (2021) -
Performance Evaluation of the Microfluidic Antigen LumiraDx SARS-CoV-2 and Flu A/B Test in Diagnosing COVID-19 and Influenza in Patients with Respiratory Symptoms
por: Ellis, Jayne E., et al.
Publicado: (2022) -
Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic
Point-of-Care Setting Compared With an Established Laboratory Reference
Method
por: Tait, Robert Campbell, et al.
Publicado: (2019) -
Utilidad del test de antígenos SARS-COV-2 de LumiraDx™ en centros residenciales
por: Domínguez Fernández, Mercedes, et al.
Publicado: (2022) -
Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2
por: Krüger, Lisa J., et al.
Publicado: (2021)